Gastric, Colorectal, and Pancreatic Adenocarcinoma clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible people ages 18 years and up
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal or pancreatic adenocarcinoma.
San Francisco, California and other locations